Idaho TB Contact Tracing Form—Return with CDC "Report of Verified Case of Tuberculosis Follow Up Report-2"

Case Name			ear Rep	oorted: _	I	Number of Contacts Identified:					
Name	Relationship to Case (family, co-worker, etc.)	Date First Evaluated	PPD Tested?	PPD Result	CXR?	CXR Result	Infection status (uninfected, infected, active TB, or unknown)	Started on PPx? (INH or other)	Date PPx Started	Date PPx Last Taken	PPX Completed? If PPx not Completed, Reason*:
Bob Contact	Brother of case	01/01/2000	Υ	10mm	Υ	Negative	Infected	Y – INH	01/06/2000	05/06/2000	No. 2

^{*}Reasons for not finishing PPx (pick the best option): 1. Death; 2. Moved AND unable to locate for follow-up; 3. Adverse effect of medication; 4. Contact chose to stop despite indication for continuation of PPx; 5. Contact lost to follow-up; 6. Provider decision

TB CONTACT INVESTIGATION REPORT

Page	of	

Today's Date:	Submitted by:	Agency:
	t; 2. Less than 5 yo; 3. Contact has med risk factor (HIV); 4. Exposed CXR consistent with previous TB; 8. 5-15yo of age	during medical procedure; 5. Exposed congregate setting;

Case Name:	County/Tribal/ IHS:
	, , ,

List of Contacts:		Contact Risk Factors	Initia	al TST	2 nd 7	Г S Т weeks	If patien old, mus	C-Ray t less than 5 years thave both r & lateral x-rays	Treatme	nt of LTBI	If Treatment is not
 Name Relationship to TB case Address 	DOB	And Dates (see above)	Date	Result mm	Date	Result mm	Date	Result	Med & Start Date	Completion Date	completed give reason
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address



Tuberculosis Contact Investigation Form

ubmitted By:	
Oate:	

Case									Contact								
Name: (last) (first)	(MI)	(also kn	own a	ıs)			Priority of exposed contact				contact	Conta	act Investigation		Contact Risk Factors		
						(please refer to CI Instructions for definitions)					1.00.1.1				Y =Yes or N = No in	chart below)	
							(pie	ase re	rer to	CI In	structions 101	r definitions)	Date		1. Househo		
DOB:	Age:	RVC	1:				Ιп	Cated	orv 1	· Sm	near nositive	or cavitary ches	*****			n 5 years of age	, (; IIII)
Morbidity Date:							┨ '''	x-ra			icai positive	or cuvitary che.	identified			has medical risk fac	
Wording Bate.								,	,				Date			during medical pro	
County:	Com	ments:						Categ	ory 2	2: Sm	near negativo	e	Interviewed:			congregate Setting	
							J									duration environme	ent limits
Type:					Cavita	ry	ΙШ	Categ	ory 3	3: Su	spect case		Date of		7. 5 - 15 ye	ears of age	
☐ Pulmonary ☐ Non Pu	lmonary C	XR Resu	lts:										Evaluation:_				
	T = .		1	<u>П</u> 1	Vonca	vitary			1				~ -	I ~ .			
Full Name	Date										TST I	Results/ QFT-	G Results	Current	Treatmen	nt of LTBI	****
of Contact	of	Ţ				ıre				~				Chest			Completion
	Birth	category	ರ	70	La	nso	1	its	Ľ	Ξ				X-Ray			Date or
		ate	To	ar	isk	ď	Sei	ij	ea	ev							Discontinued
			Household	years	Med risk	Medical exposure	Cong Set	Enviro limits	15 years	prev TB							Due to:
		*Exposure	no	3	Tec	ह्य	Or	vir	÷								
		SO	H	V		ij	C	Ţ,	N.	CXR-	ior ive	E 5 **	St # 15				
		dx'				Λe		I		C	**Prior Positive	Initial TST or QFT-G	8 – 10 week retest				
		*									**	Initial TST or QFT-G	∞ ≥ ₹				
4												Date:	Date:	Date:	Yes Date:		
1.												TST mm:	TST mm:	Normal	Drug (s)		
												OFT-G:	OFT-G:	Abnormal	No Reason:	•	
2.												Date:	Date:	Date:	Yes Date:		
2.												TST mm:	TST mm:	Normal	Drug (s)		
												QFT-G:	QFT-G:	Abnormal	☐ No Reason:	·	
3.												Date:	Date:	Date:	Yes Date:		
												TST mm:	TST mm:	☐ Normal	Drug (s)		
												QFT-G:	QFT-G:	Abnormal	No Reason:	<u> </u>	
4.												Date:	Date:	Date:	Yes Date:		
												TST mm: OFT-G:	TST mm: OFT-G:	☐ Normal ☐ Abnormal	Drug (s) No Reason:		
		 	 									Date:	Date:	Date:	Yes Date:	·	
5.												TST mm:	TST mm:	Normal	Drug (s)		
												QFT-G:	QFT-G:	Abnormal	No Reason:	·	
*Exposure Category	**Prior l	Positive	<u> </u>	1			***	Ouan	tifero	n-GC	OLD Results		,	te or discontinue			
H= High	(1) = Foll		eded					= Posi								Discontinued Meds	
M= Medium	(2) = Foll			ded				= Neg) = Died during treatment (R) = Refused to conti				
L= Low		-					(3) =	= Inde	termi	nate			L) = Lost			(T) = TB Dise	ase Diagnosed
							(M) =) = Moved & Records Referred							

TB Contact Investigation Summary Due at the completion of each contact investigation - After all contacts on treatment for LTBI have completed therapy or have discontinued drug therapy Montana Department of Public Health & Human Services Today's Date _____ TB Program, Cogswell Building, Room C-216 Submitted by _____ Date Case Reported _____ 1400 Broadway, Helena, MT 59620 Phone: 406-444-0275; Fax: 406-444-0272 County _____ Case Name ____ ___ pulmonary TB with AFB sputum smear positive 1. The case had: ___ pulmonary TB with AFB sputum smear negative (check one) ___ non-pulmonary TB other 2. Number of contacts identified _____ 3. Number of contacts evaluated (initial TST placed & read, follow-up TST placed & read if indicated, and chest x-ray) 4. Number of contacts that were diagnosed with active TB disease as a result of this contact investigation _____ (This will trigger a separate contact investigation.) 5. Number of contacts that were diagnosed with latent TB infection (LTBI) as a result of this contact investigation _ a. Number that started treatment for LTBI ____ b. Number of contacts that completed recommended treatment _____ 6. For contacts not completing treatment for LTBI: a. Number who died before completing therapy __ b. Number who moved before completing therapy with no follow-up information _____ c. Number who developed active TB disease during the course of therapy d. Number who stopped treatment due to side effects/adverse reactions _____ e. Number who chose to stop treatment without any contraindications _____ f. Number who stopped treatment on provider's advice _____ g. Number lost to follow-up _____ Evaluation Indices for Contact Investigation: 1. Percentage of contacts evaluated _____ (MT goal: 95% of contacts to AFB-positive smear cases are evaluated) 2. Percentage of contacts who were diagnosed with LTBI _____ 3. Percentage of contacts with LTBI who completed treatment _____ (MT goal: 80% of contacts with LTBI will complete treatment)